Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
230.26
-6.19 (-2.62%)
At close: Nov 20, 2026, 4:00 PM EST
230.62
+0.36 (0.16%)
After-hours: Nov 20, 2026, 7:30 PM EST
Jazz Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 22 analysts polled by S&P Global, Jazz Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $297.5. The average 1-year stock price forecast is 29.20% higher than the current stock price, while the lowest is $220 (-4.46%) and the highest is $330 (+43.32%).
Price Target: $297.5 (+29.20%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Jazz Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 11 | 11 | 13 | 13 | 13 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 20 | 20 | 22 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Buy Maintains $310 → $308 | Buy | Maintains | $310 → $308 | +33.76% | Nov 16, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $319 → $324 | Buy | Maintains | $319 → $324 | +40.71% | Nov 13, 2026 |
| UBS | UBS | Buy Maintains $326 | Buy | Maintains | $326 | +41.58% | Nov 13, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $310 → $330 | Buy | Reiterates | $310 → $330 | +43.32% | Nov 12, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $313 | Buy | Reiterates | $313 | +35.93% | Nov 3, 2026 |
Financial Forecast
Revenue This Year
4.81B
from 4.27B
Increased by 12.68%
Revenue Next Year
5.07B
from 4.81B
Increased by 5.34%
EPS This Year
14.90
from 8.38
Increased by 77.86%
EPS Next Year
26.74
from 14.90
Increased by 79.43%
EPS and Forward PE are based on non-GAAP adjusted numbers.